Key Documents

View All Documentation

1134153

USP

Cilostazol

Name: Cilostazol
Brand: USP

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone, OPC 13013, OPC 21, Pletaal

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₂₀H₂₇N₅O₂

CAS Number:

73963-72-1

Molecular Weight:

369.46

NACRES:

NA.24

PubChem Substance ID:

329749401

UNSPSC Code:

41116107

MDL number:

MFCD00866780

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

grade

pharmaceutical primary standard

API family

cilostazol

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

O=C1CCc2cc(OCCCCc3nnnn3C4CCCCC4)ccc2N1

InChI

1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)

InChI key

RRGUKTPIGVIEKM-UHFFFAOYSA-N

Gene Information

human ... PDE3A(5139)

Description

General description

Cilostazol is a potent cyclic nucleotide phosphodiesterase inhibitor. It is mainly used as antiplatelet agent.

Application

Cilostazol USP Reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monograph such as Cilostazol Tablets

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.

Other Notes

Sales restrictions may apply.

Still not finding the right product?

Explore all of our products under Cilostazol

pictograms

GHS08

signalword

Warning

hcodes

H361d

pcodes

P201 - P202 - P280 - P308 + P313 - P405 - P501

Hazard Classifications

Repr. 2

Storage Class

11 - Combustible Solids

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: a meta-analysis of 5,821 patients.

Deng-Feng Geng et al.

Cardiology, 122(3), 148-157 (2012-07-27)

Uncertainties still remain in terms of what kinds of patients benefit most from cilostazol-based triple antiplatelet therapy (TAT) after coronary stenting. We performed a meta-analysis of all relevant randomized controlled trials (RCTs) to investigate the effect of TAT versus dual

A meta-analysis of randomized controlled trials appraising the efficacy and safety of cilostazol after coronary artery stent implantation.

Jae-Sik Jang et al.

Cardiology, 122(3), 133-143 (2012-07-27)

To evaluate the impact of cilostazol on the angiographic and clinical outcomes in patients undergoing percutaneous coronary intervention (PCI) with stents and treated with aspirin and thienopyridine. A total of 11 randomized controlled trials including 8,525 patients comparing triple antiplatelet

Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture.

S Takahashi et al.

Journal of cardiovascular pharmacology, 20(6), 900-906 (1992-12-01)

Cilostazol, a cyclic AMP phosphodiesterase inhibitor, has been used as an antiplatelet agent. In the present study, we investigated the in vitro effect of cilostazol on DNA synthesis in rat aortic arterial smooth muscle cells (SMCs) in culture stimulated with

View All Related Papers

Global Trade Item Number

SKU	GTIN
1134153-200MG	04061838701121